

**Regenerative Medicine Minnesota  
Board Meeting August 30, 2017 via conference call**

Board members attending: Margaret Anderson Kelliher, Roberta King, Ven Manda, Andre Terzic, Jakub Tolar

Board members absent: none

Guests: Beth Borg, Nancy Morgan

The meeting was called to order at 11:03 AM.

The Board was apprised that the June Celebration at Mayo had been a great success. The five-minute update video shown at the meeting is available at [www.regenmedmn.org](http://www.regenmedmn.org).

**The Board was asked to comment on the 2018-2019 RMM Business Plan draft distributed prior to the meeting with minor changes.**

Board discussed and approved of the minor rewording on page 1, to increase grant amounts for patient care to \$50K on page 2, and to the division of college education programs into Undergraduate (award limit \$50K) and Graduate (including PhD, award limit \$75K) on page 3. A revised draft will be circulated for final approval.

Discussion of how success of programs should be evaluated going forward. Proposed measures included: success in outcomes of regenerative medicine therapies, focus on areas of great need in the state of MN, creation of jobs/retention of investigators, and increased investigator activity related to the grant.

Discussion of how to develop patient care program in addition to raising grant amount. These grants are aimed at small, outstate hospitals and clinics to help them hire personnel or to purchase equipment or products that will allow them to provide regenerative therapies to their patients.

There was a suggestion to split Biotechnology/Biobusiness into two subcategories. This RFP is undergoing revision. Further changes to Biotechnology/Biobusiness will be addressed at the next Board meeting.

After discussion, the Board agreed to not make changes to the funding distribution or to the four funding categories at this time because RMM does have a patient care component and should keep a focus on care delivery.

It was noted that the current amount of Biotechnology/Biobusiness awards is not enough to see significant biotech development. Analysis of past funding might provide helpful information, and additional funds for this category would be especially desirable. One suggestion is to require 1:1 matching for these proposals. This will be discussed with the RFP revision at the next meeting.

**The Board was asked to comment on the 2017-2018 Research Grant RFPs.**

The Board discussed and approved changes to the RFPs as follows:

- Align the RMM's policy toward early stage investigators to that of the NIH.
- Add emphasis on job creation.
- Focus on chronic disease in MN.

- Remind applicants of FOIA applicability and the need to mark proprietary information.

It was clarified that if there are no early stage investigator proposals worthy of funding, that all funding would go to worthy established investigator proposals. Scientific merit remains the primary basis of award.

The Business Plan and all three research grant RFPs will be redrafted and redistributed for Board vote via email so that they are ready for distribution on 9/11/2017.

The business being concluded, the meeting was adjourned at 12:00 noon.